Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00358397 · ClinicalTrials.gov registry record · Phase 1

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Terminated
Registry status
Phase 1
Development phase
2
Enrollment target

NCT00358397 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00358397, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

TERMINATED
Registry status
Phase 1
Development phase
2 participants
Enrollment target

Study Summary

This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.

Interventions

  • DRUG Clostridium novyi-NT spores

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2006-07
Est. Completion 2008-09
Phase Phase 1

What the Registry Record Tells You About NCT00358397

The ClinicalTrials.gov registry entry for NCT00358397 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Clostridium novyi-NT spores is the first listed.

NCT00358397 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00358397 about?

NCT00358397 is a clinical study titled "One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy". This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.

What is the current status of trial NCT00358397?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2006-07. Estimated completion is 2008-09.

What interventions are being tested in trial NCT00358397?

The interventions under investigation include: Clostridium novyi-NT spores (DRUG).

Who is sponsoring clinical trial NCT00358397?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.